With repeated drug failures to treat Alzheimer’s disease in recent years, scientists are racing to find a vaccine to prevent the disease from evolving. The latest study was tested on mice genetically programmed to get Alzheimer’s disease and was successful in removing beta-amyloid plaque and tau protein linked to Alzheimer’s disease in the animals.
This latest vaccine study was conducted by researchers at the University of California Irvine and used an adjuvant or an immunological agent that boosts the immune response of the vaccine, formulated by Flinders University in South Australia.
With repeated drug failures to treat Alzheimer’s disease in recent years, scientists are racing to find a vaccine to prevent the disease from evolving. The latest study was tested on mice genetically programmed to get Alzheimer’s disease and was successful in removing beta-amyloid plaque and tau protein linked to Alzheimer’s disease in the animals.
This latest vaccine study was conducted by researchers at the University of California Irvine and used an adjuvant or an immunological agent that boosts the immune response of the vaccine, formulated by Flinders University in South Australia.
“Our approach is looking to cover all bases and get past previous roadblocks in finding a therapy to slow the accumulation of amyloid beta/tau molecules and delay Alzheimer’s disease progression in a the rising number of people around the world,” says Flinders University Professor Petrovsky, who will work in the US for the next three months.
